Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
This research is a 'Phase II' study, which means it's an early look into combining two existing medicines for people who have just been diagnosed with Polycythemia Vera. The two medicines are called Peginterferon alfa-2a and Ruxolitinib, also known as Jakavi. Doctors are trying to find out how safe this combination of treatments is. They will also be observing how well the medicines help control the condition, such as whether they can reduce certain blood counts to healthy levels and if they lower the chance of problems like blood clots or bleeding. The study aims to gather important information to help future patients with Polycythemia Vera.
A colpo d'occhio
Di cosa tratta questo studio?
This study is looking at a condition called Polycythemia Vera. This is a rare blood disorder where your body makes too many red blood cells, and sometimes too many white blood cells and platelets too. Having too many of these blood cells can make your blood thicker, increasing the risk of serious problems like blood clots or bleeding. This study wants to see if combining two specific medicines might be a good new way to help people who have just been diagnosed with this condition.
The two medicines being tested are Peginterferon alfa-2a and Ruxolitinib. Peginterferon alfa-2a is a type of medicine that helps control how your bone marrow makes blood cells. Ruxolitinib, also known by its brand name Jakavi, works by targeting specific signals in your body that can lead to too many blood cells being made.
The main goal of this study is to carefully watch for any side effects or problems that might happen when these two medicines are used together. This helps doctors understand how safe the combination is. They will also be checking to see if these medicines work well together to manage Polycythemia Vera, for example, by bringing blood cell counts back to normal ranges and reducing the risk of complications over time.
Punti chiave
- This study is for newly diagnosed adults with Polycythemia Vera.
- It tests a combination of two established medicines, Peginterferon alfa-2a and Ruxolitinib (Jakavi).
- The main focus is on how safe the combination treatment is.
- Researchers also want to see if the treatment helps control blood counts and prevents complications.
- Participants will have regular check-ups and blood tests over up to two years.
- Your decision to join or leave the study will not affect your standard medical care.
Chi può essere idoneo?
To be able to join this study, there are a few important things that need to be true about you.
First, you must be an adult aged 18 years or older. There is no upper age limit, meaning people of all adult ages can be considered. Also, both men and women can take part in this research.
Because this study is looking at new ways to treat people who have just found out they have Polycythemia Vera, you would typically need to have received your diagnosis recently. The doctors running the study will have other specific medical criteria to make sure the study treatment is right for you, and that it's safe for you to participate.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Have you recently been diagnosed with Polycythemia Vera (not a long-term condition)?
- Are you able to attend regular hospital or clinic appointments?
- Do you feel comfortable taking study medication as instructed?
- Do you understand that there might be specific medical criteria your doctor will check?
Cosa comporta la partecipazione?
If you decide to take part in this study, you would first have some checks to make sure the study is right for you. If you qualify, you would then start taking the two study medications, Peginterferon alfa-2a and Ruxolitinib, as prescribed by the study doctors. You would have regular appointments at the hospital or clinic. These visits would involve check-ups, blood tests, and discussions with the study team to monitor your health and see how the treatment is working and if you are having any side effects. The exact number of visits and tests would be explained to you, but they would happen over a period of up to two years, with follow-up appointments at specific times like 3, 6, 9, 12, 18, and 24 months. You would continue to receive careful medical care throughout your time in the study.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoDanimarca
Domande comuni
What is Polycythemia Vera?
It's a blood disorder where your body makes too many blood cells, which can make your blood thicker and increase the risk of clots.
What medicines are being tested?
The study is looking at a combination of Peginterferon alfa-2a and Ruxolitinib (Jakavi).
Why combine these two medicines?
Researchers want to see if using these medicines together is safer and works better for controlling Polycythemia Vera.
Quanto durerà lo studio?
Participants will be followed for up to 24 months (two years) to see how the treatment works over time.
Posso smettere di partecipare se lo desidero?
Yes, you can leave the study at any point without it affecting your normal medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.